UnknownPhase 2NCT02571829
A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma
Studying Well-differentiated liposarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hadassah Medical Organization
- Principal Investigator
- Daniela Katz, MDHadassah Medical Organization
- Intervention
- ribociclib(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2017
Study locations (1)
- Hadassah Medical Organization, Jerusalem, Israel
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02571829 on ClinicalTrials.govOther trials for Well-differentiated liposarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06843967A Study of Mirdametinib in Combination With Palbociclib in People With LiposarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGNANCT04224064Identification of a New Blood Biomarker for the Diagnosis and Prognosis of LiposarcomasInstitut du Cancer de Montpellier - Val d'Aurelle